MedPath

Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home

Not Applicable
Completed
Conditions
Overactive Bladder
Interventions
Device: TENS
Registration Number
NCT03595215
Lead Sponsor
Theranova, L.L.C.
Brief Summary

This pilot clinical study, which focuses on feasibility and proof-of-principle, will be conducted in 11 female subjects (55-100 years old) with UI. Subjects will use the device three times a week for 8 weeks and complete 3-day "voiding diaries" to record instances of UI episodes and OAB quality of life.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
18
Inclusion Criteria
  1. Females
  2. 55-100 years old
  3. Have an average urinary frequency of ≥ 8 voids per 24 hours (based on a pre-treatment 3-day voiding "training" diary)
  4. Have self-reported bladder symptoms of more than 3 months
  5. Are ambulatory and able to use the toilet independently
  6. Have been off antimuscarinics, anticholinergics or beta-3 agonists for at least 2 weeks prior to enrollment OR on a stable dose for the prior 3 months
  7. Patient has urinary urge incontinence of ≥ 8 episodes from a 3-day diary (with incontinence associated at urge level moderate or severe)
  8. Able to provide informed consent
  9. Capable and willing to follow all study-related procedures
Exclusion Criteria
  1. Have primary complaint of stress urinary incontinence
  2. Have a pacemaker or implantable defibrillator
  3. Had botox injections in the bladder or pelvic floor muscles in the past 12 months
  4. Have a current urinary tract or vaginal infection
  5. Have an active implantable SNS device (InterStim & Bion)
  6. Have been diagnosed with peripheral neuropathy or nerve damage
  7. Currently pregnant
  8. Deemed unsuitable for enrollment in study by the investigator based on subjects' history or physical examination

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
TENS Treatment ArmTENSThis study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
Primary Outcome Measures
NameTimeMethod
Change in Urge Incontinence EpisodesBaseline and 8 weeks
Secondary Outcome Measures
NameTimeMethod
Change in Micturitions Per DayBaseline and 8 weeks

Mean number of urinary voids per day (taken over a 3-day period)

Change in Health-related Quality of Life (HRQL)Baseline and 8 weeks

Change in incontinence health-related quality of life (HRQL) scores compared to pre-treatment. The survey consists of 13 questions that can be scored from 1 to 6. Lower scores correspond with better quality of life. The lowest score possible is 13 and the highest is 78.

Trial Locations

Locations (1)

Stanford University Medical Center

🇺🇸

Palo Alto, California, United States

© Copyright 2025. All Rights Reserved by MedPath